Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

OTHER RELATED OMICS DATASETS IN: E-GEOD-51005

PROVIDER: PRJNA219507 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR993713_1.fastq.gz	Fastqsanger.gz
	SRR993713_2.fastq.gz	Fastqsanger.gz
	SRR993714_1.fastq.gz	Fastqsanger.gz
	SRR993714_2.fastq.gz	Fastqsanger.gz
	SRR993715_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

E-GEOD-51005

Project description:Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

2025-01-24 | E-GEOD-51005 | ExpressionAtlas

Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

Project description:Early chemotherapy for advanced/metastatic non-castration resistant prostate cancer (PCa) may improve overall patient survival. We studied the safety, tolerability and early efficacy of up-front docetaxel chemotherapy and androgen deprivation therapy (ADT) versus ADT alone for patients with newly-diagnosed advanced/metastatic PCa. As proof of concept, we undertook in vivo gene expression profiling by next generation RNA sequencing (RNA-Seq).

2014-09-18 | GSE51005 | GEO

Next generation sequencing of advanced non-castrate prostate cancer treated with docetaxel chemotherapy

2014-09-18 | E-GEOD-51005 | biostudies-arrayexpress

E-GEOD-48403

Project description:Transcription profiling by high throughput sequencing of advanced prostate cancer treated with androgen-deprivation therapy

2025-01-24 | E-GEOD-48403 | ExpressionAtlas

E-GEOD-33455

Project description:Expression data from docetaxel-resistant prostate cancer cell lines

2025-01-24 | E-GEOD-33455 | ExpressionAtlas

E-MTAB-9484

Project description:RNA-seq analysis of TCEAL1 knock down with/without docetaxel treatment to enhance docetaxel efficacy in prostate cancer

2025-01-23 | E-MTAB-9484 | ExpressionAtlas

In vivo CRISPR/Cas9 screen to identify candidate therapeutic gene targets to enhance docetaxel efficacy in prostate cancer

Project description:Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit due to emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR/Cas9 screen under docetaxel treatment pressure.

2020-10-07 | E-MTAB-9482 | biostudies-arrayexpress

Expression data from C4-2 prostate cancer cells treated with taxanes

Project description:Comparison of the new generation taxane cabazitaxel with docetaxel in prostate cancer cells Cabazitaxel impacts distint molecular pathways as compared to docetaxel, which could underlie its efficacy after docetaxel treatment has failed in castration resistant prostate cancer patients 12 samples were analysed. A genome-wide expression array was performed on a GeneChip Human Gene 2.0ST Array (Affymetrix, 902112) with C4-2 cells, treated for 16h with 1nM cabazitaxel, docetaxel or vehicle (EtOH), in duplicates. The expression data were RMA normalized, and filtered to remove low-expressing genes. Differential gene expression with corresponding p-values (student’s ttest) was determined of drug-treated over control.

2015-01-01 | E-GEOD-63478 | biostudies-arrayexpress

Expression data from docetaxel-resistant prostate cancer cell lines

Project description:Docetaxel-based chemotherapy is the standard first-line therapy in metastatic castration-resistant prostate cancer. However, most patients eventually develop resistance to this treatment. The aim of the study was to identify key molecular genes and networks associated with docetaxel resistance in 2 models of docetaxel-resistant castration-resistant prostate cancer cell lines.

2012-01-01 | GSE33455 | GEO

Expression data from C4-2 prostate cancer cells treated with taxanes

2015-01-01 | GSE63478 | GEO